NZOZ Medica
- Address
- lock Available on a paid plan
Autoimmune and Metabolic Diabetes Research
At NZOZ Medica in Lublin, clinical research is focused on nutritional and metabolic diseases and metabolism, with a strong emphasis on Type 1 diabetes mellitus. These studies are exploring whether new treatment approaches can help preserve insulin production, improve blood sugar control, and support better long-term disease management.
- Evaluating a new therapy for recently diagnosed Type 1 diabetes
- Assessing whether treatment can help maintain beta cell function
- Investigating improved glycemic control in adolescents and adults
This area of research is centered on finding safer and more effective ways to slow disease progression and support early intervention in people living with diabetes.
Type 2 Diabetes Treatment Optimization
Another key focus at the site is Type 2 diabetes mellitus, especially for patients whose blood sugar remains difficult to control. The trials are examining combination treatment strategies to improve everyday glucose management and strengthen the effectiveness of existing diabetes care.
- Testing add-on treatment options for Type 2 diabetes mellitus
- Studying ways to improve glycemic control when standard therapy is not enough
- Comparing combination approaches to support better treatment effectiveness
The research reflects a broader effort to refine metabolic disease treatment and identify combinations that may offer better control for people with persistent hyperglycemia.
Cardiovascular Risk in Diabetes
Clinical trials at NZOZ Medica also address the connection between cardiovascular diseases and Type 2 diabetes mellitus. These studies are designed to determine whether diabetes therapies can also help reduce serious heart-related complications in patients with elevated cardiovascular risk.
- Studying treatment effects on major cardiovascular events
- Evaluating outcomes in patients with Type 2 diabetes and high heart risk
- Comparing therapies for both glucose management and cardiovascular protection
This line of research combines diabetes care with prevention of major heart and stroke events, highlighting the site’s interest in treatments that may support both metabolic and cardiovascular health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in NZOZ Medica
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Pioglitazone with Metformin and Empagliflozin in Type 2 Diabetes Mellitus Patients with Inadequate Glycemic Control | Celltrion Inc. | Phase III | Not Recruiting | Aug 2024 | Apr 2026 |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Colecalciferol | 1 | Unknown | 2022-03-17 | 2022-03-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.